Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-26
2005-07-26
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266200, C544S284000, C544S285000
Reexamination Certificate
active
06921766
ABSTRACT:
There is provided a preventive or therapeutic agent for diseases accompanied by abnormal vascular function in which lipid deposition in the blood vessel is involved, said agent comprising a chymase inhibitor as an active ingredient.As the chymase inhibitor, a quinazoline derivative represented by the following formula is used.In the above formula, the ring A represents an aromatic ring.
REFERENCES:
patent: 5691335 (1997-11-01), Fukami et al.
patent: 5814631 (1998-09-01), Fukami et al.
patent: 5948785 (1999-09-01), Akahoshi et al.
patent: 6080738 (2000-06-01), Akahoshi et al.
patent: 6300337 (2001-10-01), Ishida et al.
patent: 6432978 (2002-08-01), Tani et al.
patent: 0 795 548 (1997-09-01), None
patent: 05 169832 (1993-07-01), None
patent: 10-053579 (1998-02-01), None
patent: 93/03625 (1993-03-01), None
patent: 93/25574 (1993-12-01), None
patent: 96/04248 (1996-02-01), None
patent: 96/33974 (1996-10-01), None
patent: 96/39373 (1996-12-01), None
patent: 97/11941 (1997-04-01), None
patent: 97/45400 (1997-12-01), None
patent: 98/18794 (1998-05-01), None
patent: 99/41277 (1999-08-01), None
patent: 00/10982 (2000-03-01), None
patent: WO-00/32587 (2000-06-01), None
Jozef Oleksyszyn et al, “Irreversible Inhibition of Serine Proteases by Peptide Derivatives of (α-Aminoalkyl)phosphonate Diphenyl Esters” Biochemistry, Jan. 15, 1991, 30, pp. 485-493.
Hidenori Urata et al, “Cloning of the Gene and cDNA for Human Heart Chymase” Biol. Chem., Sep. 15, 1991, vol. 266, No. 26, pp. 17173-17179.
Margarita Bastos, et al, “Inhibitors of human heart chymase based on a peptide library” Proc. Natl. Acad. Sci., vol. 92, Jul. 1995, pp. 6738-6742.
Jorma O. Kokkonen, et al, “Role of Mast Cell Proteases and Proteoglycans in Lipoprotein Metabolism”Mast Cell Proteases in Immunology and Biology, pp. 257-287, 1995.
Suguru Nakayama, et al, “Pathophysiological roles of human chymase” Nippon Rinsho, Aug. 1997, 55(08); pp. 1903-1908.
Shinji Takai, et al, “Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta”, FEBS Letters, Jul. 21, 1997, 412(1), pp. 86-90.
Maki Akasu, et al, “Differences in Tissue Angiotensin II-Forming Pathways by Species and Organs in Vitro” Hypertension, Sep. 1998, 32(3); pp. 514-520.
Jason L. Johnson, “Activation of Matrix-Degrading Metalloproteinases by Mast Cell Proteases in Atherosclerotic Plaques” Arterioscler Thromb Vasc Biol, Nov. 1998, 18(11), pp. 1707-1715.
Shlomo Keidar, “Angiotensin, LDL Peroxidation and Atherosclerosis” Life Sciences, 1998, vol. 63, No. 1, pp. 1-11.
Masanori Yoshizumi, et al, “Effects of endothelin-1 (1-31) on extracelular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells” British Journal of Pharmacology, 1988), 125, pp. 1019-1027.
Masanori Yoshizumi, et al, “Endothelin-1-(1-31), a novel vasoactive peptide, increases [Ca2+]iin human coronary artery smooth muscle cells” European Journal of Pharmacology 348, 1998, pp. 305-309.
Makoto Ihara, et al, “Increased Chymase-Dependent Angiotensin II Formation in Human Atherosclerotic Aorta” Hypertension, Jun. 1999, 33(6), pp. 1399-1405.
Y. Liao, et al., “The chymase-angiotensin system in humans: Biochemistry, molecular biology and potential role in cardiovascular diseases”, Canadian Journal of Cardiology, vol. 11, No. Suppl. F., pp. 13F-19F, Aug. 1995.
S. Niwata et al., “Substituted 3-(Phenylsulfonyl)-1-phenylimidazolidine-2,4-dione Derivatives as Novel Nonpeptide Inhibitors of Human Heart Chymase”, Journal of Medicinal Chemistry, vol. 40, No. 14, 1997, pp. 2156-2163.
H. Fukami et al, “Chymase: Its Pathophysiologic Roles and Inhibitors,” Current Pharmaceutical Design, vol. 4, No. 6, pp. 439-453, 1998.
K. Paananen et al, “Proteolysis and Fusion of Low Density Lipoprotein Particles Independently Strengthen The Binding to Exocytosed Mast Cell Granules”, Journal of Biological Chemistry, vol. 269, No. 3, pp. 2023-2031, 1994.
H. Bult et al, “Antiatherosclerotic activity of drags in relation to nitric oxide function”, European Journal of Pharmacology, vol. 375, Issue 1-3), pp. 157-176, Jun. 30, 1999.
Fukami Harukazu
Urata Hidenori
Burns Doane Swecker & Mathis L.L.P.
Daiichi Suntory Pharma Co., Ltd.
Raymond Richard L.
LandOfFree
Blood vessel lipid deposition-preventive agent comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blood vessel lipid deposition-preventive agent comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blood vessel lipid deposition-preventive agent comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3373352